Skip to main content

Lung Non-Small Cell Cancer clinical trials at UC Davis
7 research studies open to eligible people

  • A Study of Experimental Combination Treatment With Osimertinib and Navitoclax For EGFR-Positive Non-small Cell Lung Cancer

    open to eligible people ages 18 years and up

    This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Sacramento, California and other locations

  • A Study of the Experimental Combination of Cediranib and Olaparib in Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

    Sacramento, California and other locations

  • EGFR Inhibitor AZD9291 (Osimertinib) and Monoclonal antibodies (Necitumumab) side effects and best dosing for Lung Cancer

    “This study looks at experimental immunotherapy combination: necitumumab and osimertinib in treating Stage IV or Recurrent lung cancer”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best dose of necitumumab when given together with osimertinib in treating patients with EGFR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent) and who have progressed on a previous EGFR tyrosine kinase inhibitor. Immunotherapy with monoclonal antibodies, such as necitumumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving necitumumab with osimertinib may be a better treatment for EGFR-mutant non-small cell lung cancer.

    Sacramento, California and other locations

  • Experimental medicine and whole brain radiation therapy to treat patients with brain metastases from non-small cell lung cancer

    “Study looking at radiation therapy and experimental medicine, VX-970 for treatment of lung cancer with metastases to brain”

    open to eligible people ages 18 years and up

    This phase I trial studies the side effects and best dose of ATR kinase inhibitor M6620 (VX-970) when given together with whole brain radiation therapy in treating patients with non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors that have spread from the original (primary) tumor to the brain. ATR kinase inhibitor M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ATR kinase inhibitor M6620 together with radiation therapy may be a better treatment for non-small cell lung cancer, small cell lung cancer, or neuroendocrine tumors.

    Sacramento, California and other locations

  • Genetic testing in screening patients with lung cancer that has been or will be removed by surgery.

    “Studying the genes in a patient's tumor cells may help determine the best treatment for patients that have certain genetic changes.”

    open to eligible people ages 18 years and up

    This phase III ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

    Sacramento, California and other locations

  • Study looking at immunotherapy treatment, after surgery and chemotherapy, to treat patients with lung cancer

    “Can immunotherapy help after surgery and chemotherapy to treat lung cancer?”

    open to eligible people ages 18 years and up

    This phase III ALCHEMIST trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Sacramento, California and other locations

  • Targeted chemotherapy or placebo to treat patient with lung cancer that has been completely removed by surgery

    “Can targeted chemotherapy (Erlotinib) stop the growth of tumor cells by blocking some of the enzymes needed for cell growth?”

    open to eligible people ages 18 years and up

    This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Sacramento, California and other locations

Last updated: